Skip to content

Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma

Phase 2 Study of Neoadjuvant 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00168155
Enrollment
70
Registered
2005-09-15
Start date
2002-01-31
Completion date
2009-05-31
Last updated
2012-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Adenocarcinoma, Liver Metastases

Keywords

resectable liver metastases, colorectal adenocarcinoma, survival, neoadjuvant chemotherapy

Brief summary

When colon or rectal cancer has spread to the liver, the cancer in the liver can sometimes be removed surgically. However, the cancer has a chance or reoccurring in the liver or elsewhere in the body. This study will determine if giving chemotherapy treatment before the surgery can reduce the chances that the cancer will come back.

Detailed description

When colon or rectal cancer has spread to the liver, the cancer in the liver can sometimes be removed surgically. However, the cancer has a chance or reoccurring in the liver or elsewhere in the body. This study will determine if giving chemotherapy treatment before the surgery can reduce the chances that the cancer will come back.

Interventions

Sponsors

Pfizer
CollaboratorINDUSTRY
Alberta Health services
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* stage IV colorectal cancer isolated to the liver * one measurable lesion * metastases are completely resectable or amenable to ablation * Karnofsky \>70 * Adequate bone marrow function * adequate hepatic function * adequate renal function * informed consent

Exclusion criteria

* primary tumor not controlled by locoregional treatments * bilateral portal vein and/or hepatic artery involvement * previous chemotherapy directed at treatment of metastatic colorectal cancer * underlying acute or chronic liver disease * Gilbert's disease * patients receiving phenytoin or phenobarbital prophylaxis * presence of any concurrent medical or psychiatric condition that serves as a contraindication to surgery or chemotherapy * pregnancy * malignancy other than basal cell or squamous cell carcinoma of the skin within the preceding 5 years * use of another investigational medication concurrently or within 4 months of enrollment

Design outcomes

Primary

MeasureTime frame
disease free survival

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026